Today: 12 May 2026
Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

New York, January 14, 2026, 12:54 PM EST — Regular session

  • Snowflake shares fell roughly 1.4% in midday trading, deepening the losses from Tuesday’s selloff.
  • Barclays downgraded its rating to Equal Weight and slashed the price target to $250.
  • Investors are focused on whether the stock can climb back above crucial technical levels before the upcoming earnings report.

Snowflake Inc (SNOW) shares slipped 1.4%, reaching $206.52 by midday Wednesday, deepening a slide triggered by a broker downgrade earlier this week.

Risk appetite waned across U.S. stocks, dragging the tech-focused Invesco QQQ Trust down around 1.6%, while the S&P 500 ETF slipped about 1%. Shares of data and monitoring software firms Datadog and MongoDB also fell.

Tuesday’s sell-off hit Snowflake hard, with shares falling roughly 5.1%, following a downgrade from Barclays. The stock saw heavier-than-usual trading volume, MarketBeat data shows.

Barclays downgraded Snowflake from “Overweight” to “Equal Weight,” signaling a forecast for the stock to track its sector more closely. The price target was slashed to $250 from $290. The bank cited a 42% rally priced into 2025, noting that rising expectations and increased competition for new workloads have created an “unfavorable setup” for the shares. TipRanks

Snowflake tumbled below a key technical level, slipping under its 200-day moving average—an important momentum gauge for traders—near $213 on Tuesday. According to Nasdaq data, the stock hasn’t climbed back above that mark since.

The downgrade hits a stock that has already reacted sharply to shifts in its growth outlook. Back in early December, Snowflake shares dropped after the company predicted slower product revenue growth for the fourth quarter. CEO Sridhar Ramaswamy explained this was due to improved pricing on large, long-term contracts that “don’t tend to have an immediate impact on revenue.” Reuters

Analysts are divided on how much upside has already been baked in. Benzinga’s recent ratings roundup puts the average 12-month price target near $285.57, while the lowest comes from Barclays, pegged at $250.

Snowflake offers a cloud-based platform that enables companies to store and analyze data across public clouds. A large chunk of its revenue depends on customer usage, causing quarterly results to fluctuate when clients adjust their spending up or down.

Investors aiming to buy the dip face a clear risk. If enterprise cloud budgets stall or competitors snag new data workloads, Snowflake’s stock could drop again — even if the company keeps expanding. This is all the more true when valuation is the key battleground for bulls and bears alike.

Traders are closely monitoring if the stock can steady itself after the selloff triggered by the downgrade and if additional broker reports emerge ahead of earnings season. Pushing back above the 200-day moving average would quickly reveal whether the decline was largely technical or signals a more serious issue.

The company’s upcoming earnings report is the next major event, slated for after the close on March 4, per Yahoo Finance’s earnings calendar.

Stock Market Today

  • HSIC Posts Robust Q1 2026 Sales and Margin Gains Driven by U.S. Dental, Technology Units
    May 12, 2026, 12:09 PM EDT. Henry Schein Inc. (HSIC) delivered strong sales and margin growth in the first quarter of 2026. The U.S. Dental segment led the rise, supported by solid performance in technology divisions. These gains highlight continued demand in healthcare supply and technology services, underpinning HSIC's solid market position. Investors will watch upcoming earnings for further details on segment contributions and outlook amid evolving healthcare needs.

Latest article

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

12 May 2026
Hims & Hers Health shares fell 14.6% to $24.89 Tuesday after a Q1 net loss of $92.1 million, reversing a $49.5 million profit a year ago. Revenue rose 4% to $608.1 million, but gross margin dropped to 65% from 73% as the company shifted from compounded GLP-1s to branded drugs like Wegovy and Ozempic. Subscribers climbed to 2.584 million, while monthly revenue per subscriber slipped to $80.
POET Stock Rebounds as New COO Gives AI-Photonics Rally a Fresh Test

POET Stock Rebounds as New COO Gives AI-Photonics Rally a Fresh Test

12 May 2026
POET Technologies named Sandeep Kumar as chief operating officer, triggering a 2.95% stock rise to $14.31 on heavy volume after shares hit $15.15 intraday. Kumar, formerly of Silicon Labs, will oversee Malaysia manufacturing as the company targets high-volume production. The move comes after Marvell canceled Celestial AI orders, which had weighed on the stock. Broader tech indices fell Tuesday, but POET shares outperformed.
IREN Stock Slips as Nvidia Deal Runs Into the Price of Building AI Capacity

IREN Stock Slips as Nvidia Deal Runs Into the Price of Building AI Capacity

12 May 2026
IREN shares fell about 2.4% to $53.80 Tuesday after the company priced an upsized $2.6 billion convertible-note sale, raising concerns over funding costs and dilution. The notes carry a 1% coupon and can convert at $73.07 per share. IREN reported a $247.8 million net loss last quarter. Peers Cipher Digital, Riot Platforms, and Marathon Digital also traded lower.

Popular

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

13 December 2025
Pfizer shares closed up 0.19% at $25.85 Friday, with after-hours trading lifting the stock slightly to $25.88. The company declared a $0.43 per-share quarterly dividend, payable March 6, 2026. Investors also reacted to reports of a possible FDA “black box” warning for COVID-19 vaccines and new late-stage data on breast-cancer drug Tukysa.
Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle
Previous Story

Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle

Freeport-McMoRan stock climbs as copper hits a fresh record — what to watch next for FCX
Next Story

Freeport-McMoRan stock climbs as copper hits a fresh record — what to watch next for FCX

Go toTop